Wedbush Sees 64% Upside in Infleqtion with New Outperform Rating
Full neutral-atom quantum stack highlighted as a major advantage.
Already have an account? Sign in.
Full neutral-atom quantum stack highlighted as a major advantage.
BMO Capital gives Trevi Therapeutics an Outperform rating and $36 target, citing strong potential for Haduvio as a first-in-class treatment for chronic cough in idiopathic pulmonary fibrosis.
Analyst forecasts show Intel and Samsung struggling to close the gap on A16 and N2 technology.
Genuine Parts lowered its 2026 profit outlook amid weaker consumer demand. CEO Will Stengel denied rumors of a rival acquiring its automotive business.